Dulaglutide preserves kidney function and maintains metabolic control at
a 36-month follow-up
Abstract
The renal benefits of glucagon-like peptide-1 receptor agonists (GLP-1
RA) are based mainly on preservation of glomerular filtration and a
reduction in macroalbuminuria. In controlled studies dulaglutide has
shown good metabolic rate and slows the progression of glomerular
filtration rate (GFR) loss. We analyzed, the metabolic control, the
renal preservation data based on estimated GFR (eGFR) and the
relationship of eGFR changes with baseline values at 36 months (M)
follow–up. The results shows: glycated hemoglobin was reduced −1.4% at
12M, (p<0.001), fasting blood glucose showed a significant
reduction (−30 mg/dL) at 12M (p=0.005), weight showed a 3.6 kg reduction
at 12M (p=0.009). GFR did not show a worsening during follow-up:
baseline value was 88.10±26.47 ml/min/1.73m2 and remained stable
(83.25±29.27 ml/min/1.73m2; p=0.134) at the end of the study. Based on
the 36M follow-up results, dulaglutide was shown to be an effective and
nephroprotective drug in diabetic patients.